Joint trajectories of the non-HDL-cholesterol to HDL-cholesterol ratio and physical activity, lipid-lowering medication, and incident cardiovascular disease: a landmark analysis in two ageing cohorts
Background The non-HDL-cholesterol to HDL-cholesterol ratio (NHHR) summarises atherogenic lipid burden and predicts cardiovascular disease (CVD), and guideline management pairs lipid-lowering medication with advice to be physically active. Published trajectory studies, however, have modelled NHHR alone (typically in untreated samples) and have not asked how physical activity shapes risk within NHHR trajectory classes. We therefore modelled the two exposures jointly and tested how lipid-lowering treatment modifies the resulting risk pattern. Methods We included 4,150 English Longitudinal Study of Ageing participants aged ≥ 50 with NHHR and physical activity measurements at three waves (2004, 2008, 2012). Group-based multivariate trajectory modelling identified five joint NHHR–activity classes (mean posterior assignment probability 0.85). Incident CVD was ascertained from the 2012 landmark to 2018 in Cox models with three adjustment levels; medication comparisons used inverse-probability-of-treatment weighting. The untreated-population analysis was repeated in CHARLS. Results Mean age was 68.3 years (SD 8.1), 55.5% of participants were women, and 577 developed CVD over 21,852 person-years. Relative to the reference class (moderate NHHR, high activity), fully adjusted hazard ratios were 1.43 (95% CI 1.03–1.97) for the high-NHHR/low-activity class and 1.51 (1.02–2.22) for the isolated-high-NHHR class, but 0.99 (0.70–1.38) for the class whose NHHR fell alongside low activity. Within treated participants, achieved NHHR did not predict events (0.88, 0.70–1.12). Comparing the two low-activity classes, which shared the highest prevalence of lipid-lowering treatment (36% each), the class whose NHHR remained high carried 67% higher risk than the class whose NHHR fell (1.67, 1.03–2.73). Achieved NHHR predicted events in untreated participants (1.29 per unit, 1.09–1.52); the untreated gradient replicated in CHARLS (1.32, 1.08–1.62). Conclusion Joint NHHR–activity trajectories stratify CVD risk beyond either exposure alone. Lipid-lowering treatment flattens the NHHR–risk gradient, and among the two low-activity classes that shared the highest treated prevalence, the class whose NHHR remained high faced the greatest excess. Joint trajectory assessment may refine risk stratification in treated dyslipidaemia.
Authors
- Lingfeng Yang (ORCID: https://orcid.org/0000-0001-8451-7848)
- Weiguo Li
- Xin Yang¹
Publication Details
- Journal
- Research Square
- Published
- 2026-11-18
- DOI
- https://doi.org/10.21203/rs.3.rs-11544811/v1
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- preprint